BACKGROUND/AIMS: Pancreatic adenocarcinoma (PC) harbors frequent alterations in p16, resulting in cell cycle dysregulation. A phase I study of docetaxel and flavopiridol, a pan-cyclin-dependent kinase inhibitor, demonstrated encouraging clinical activity in PC. This phase II study was designed to further define the efficacy and toxicity of this regimen in patients with previously treated PC. METHODS: Patients with gemcitabine-refractory, metastatic PC were treated with docetaxel 35 mg/m(2) followed by flavopiridol 80 mg/m(2) on days 1, 8, and 15 of a 28-day cycle. Tumor measurements were performed every two cycles. A Simon two-stage design was used to evaluate the primary endpoint of response. RESULTS: Ten patients were enrolled, and 9 were evaluable for response. No objective responses were observed; however, 3 patients (33%) achieved transient stable disease, with one of these patients achieving a 20% reduction in tumor size. Median survival was 4.2 months, with no patients alive at the time of analysis. Adverse events were significant, with 7 patients (78%) requiring >or=1 dose reduction for transaminitis (11%), grade 4 neutropenia (33%), grade 3 fatigue (44%), and grade 3 diarrhea (22%). CONCLUSIONS: The combination of flavopiridol and docetaxel has minimal activity and significant toxicity in this patient population. These results reflect the challenges of treating patients with PC in a second-line setting where the risk/benefit equation is tightly balanced. Copyright 2009 S. Karger AG, Basel.
BACKGROUND/AIMS: Pancreatic adenocarcinoma (PC) harbors frequent alterations in p16, resulting in cell cycle dysregulation. A phase I study of docetaxel and flavopiridol, a pan-cyclin-dependent kinase inhibitor, demonstrated encouraging clinical activity in PC. This phase II study was designed to further define the efficacy and toxicity of this regimen in patients with previously treated PC. METHODS:Patients with gemcitabine-refractory, metastatic PC were treated with docetaxel 35 mg/m(2) followed by flavopiridol 80 mg/m(2) on days 1, 8, and 15 of a 28-day cycle. Tumor measurements were performed every two cycles. A Simon two-stage design was used to evaluate the primary endpoint of response. RESULTS: Ten patients were enrolled, and 9 were evaluable for response. No objective responses were observed; however, 3 patients (33%) achieved transient stable disease, with one of these patients achieving a 20% reduction in tumor size. Median survival was 4.2 months, with no patients alive at the time of analysis. Adverse events were significant, with 7 patients (78%) requiring >or=1 dose reduction for transaminitis (11%), grade 4 neutropenia (33%), grade 3 fatigue (44%), and grade 3 diarrhea (22%). CONCLUSIONS: The combination of flavopiridol and docetaxel has minimal activity and significant toxicity in this patient population. These results reflect the challenges of treating patients with PC in a second-line setting where the risk/benefit equation is tightly balanced. Copyright 2009 S. Karger AG, Basel.
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Christopher M Halloran; Paula Ghaneh; Susannah Shore; William Greenhalf; Lou Zumstein; Deborah Wilson; John P Neoptolemos; Eithne Costello Journal: J Gene Med Date: 2004-05 Impact factor: 4.565
Authors: C Caldas; S A Hahn; L T da Costa; M S Redston; M Schutte; A B Seymour; C L Weinstein; R H Hruban; C J Yeo; S E Kern Journal: Nat Genet Date: 1994-09 Impact factor: 38.330
Authors: Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2012-02-07 Impact factor: 3.167
Authors: Bhuvaneswari Ramaswamy; Mitch A Phelps; Robert Baiocchi; Tanios Bekaii-Saab; Wenjun Ni; Ju-Ping Lai; Anna Wolfson; Mark E Lustberg; Lai Wei; Deidre Wilkins; Angela Campbell; Daria Arbogast; Austin Doyle; John C Byrd; Michael R Grever; Manisha H Shah Journal: Invest New Drugs Date: 2010-10-12 Impact factor: 3.850
Authors: Keqing Wang; Peter Hampson; Jon Hazeldine; Vladimir Krystof; Miroslav Strnad; Paul Pechan; Janet M Journal: PLoS One Date: 2012-01-19 Impact factor: 3.240